D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Omeros (NASDAQ:OMER) with a price target of $36.00.
• The current consensus rating for Omeros among analysts is "Moderate Buy," with a target price of $18.00.
• Omeros has a market cap of $224.40 million and traded at $3.83, significantly lower than its 12-month high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating reaffirmed by D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $36.00 price objective on the biopharmaceutical company's stock.

Other equities research analysts also recently issued reports about the stock. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Omeros in a research note on Friday, June 27th. Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Price Performance

Omeros stock traded up $0.24 during mid-day trading on Friday, hitting $3.83. The company's stock had a trading volume of 5,311,184 shares, compared to its average volume of 840,306. The stock has a market cap of $224.40 million, a price-to-earnings ratio of -1.45 and a beta of 2.16. The business has a 50 day moving average price of $3.35 and a 200-day moving average price of $6.36. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last issued its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). On average, equities research analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of Omeros in the 4th quarter valued at approximately $124,000. Quantbot Technologies LP acquired a new stake in shares of Omeros during the 4th quarter worth $46,000. JPMorgan Chase & Co. boosted its stake in Omeros by 31.3% in the fourth quarter. JPMorgan Chase & Co. now owns 32,134 shares of the biopharmaceutical company's stock valued at $317,000 after buying an additional 7,667 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Omeros by 153.4% in the fourth quarter. Alliancebernstein L.P. now owns 50,990 shares of the biopharmaceutical company's stock valued at $504,000 after buying an additional 30,870 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Omeros in the fourth quarter valued at about $130,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.